Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.5767
+0.03015.51%
Post-market: 0.58990.0132+2.29%19:59 EDT
Volume:2.46M
Turnover:1.41M
Market Cap:168.40M
PE:-2.89
High:0.5845
Open:0.5527
Low:0.5527
Close:0.5466
Loading ...

Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
06 Nov 2024

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
05 Nov 2024

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
02 Nov 2024

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
01 Nov 2024

Promising Developments in Ocugen’s Pipeline Support Buy Rating

TIPRANKS
·
30 Oct 2024

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
30 Oct 2024

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
29 Oct 2024

BRIEF-Ocugen Clinical Showcase Highlighting Progress In Retinal Gene Therapy Clinical Trials In New York City On Tuesday, November 12, 2024

Reuters
·
28 Oct 2024

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

THOMSON REUTERS
·
28 Oct 2024

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

GlobeNewswire
·
28 Oct 2024

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
25 Oct 2024

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
24 Oct 2024

Ocugen Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Oct 2024

Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease

MT Newswires Live
·
22 Oct 2024

Ocugen announces DSMB for OCU410ST trial approved enrollment for second phase

TIPRANKS
·
22 Oct 2024